One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre

BACKGROUND: Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG). However, 1 year of PCV is associated with significant toxicities. In the pivotal RTOG 9802 randomised control trial, approximately half of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Keogh, Rachel J., Aslam, Razia, Hennessy, Maeve A., Coyne, Zac, Hennessy, Bryan T., Breathnach, Oscar S., Grogan, Liam, Morris, Patrick G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869199/
https://www.ncbi.nlm.nih.gov/pubmed/33557783
http://dx.doi.org/10.1186/s12885-021-07809-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869199/
https://www.ncbi.nlm.nih.gov/pubmed/33557783
http://dx.doi.org/10.1186/s12885-021-07809-5

Ejemplares similares